Browse drugs

…es are shown in bold where p<0.05.Conclusion Patients receiving mepolizumab achieve early responses with significant overall symptom VAS an…

…ling of the airways, typically resistant to standard therapies. Mepolizumab, an anti-IL-5 biologic, reduces eosinophil levels and improves …

…Background Mepolizumab, a monoclonal antibody to interleukin-5, has been shown to redu…

…crease (~8%) in methylation between baseline and 3 months among Mepolizumab responders, while non-responders exhibited an increase (~4%). A…

…llected by bronchoscopy at baseline (T0) and 6 months (T6) post mepolizumab treatment ( NCT05144087, GSK funded, investigator led study). F…

…umab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent pati…

…-year analyses from the real-world REALITI-A study demonstrated mepolizumab improvements in asthma control and lung function, a key outcome…

…olled patients (≥18 years) with severe asthma, newly prescribed mepolizumab (100-mg subcutaneously). Changes from baseline in asthma contro…

…enralizumab, dupilumab, mepolizumab, omalizumab, reslizumab and tezepelumab, were estimated using Medicine Carbon Footprint Classifier, a s…

…pport co-prescribing. We describe our experience of prescribing benralizumab alongside non-SA MAbs at a tertiary centre.Methods We conducted…

…enced relapses and intolerance to azathioprine. Introduction of mepolizumab, an anti-IL-5 monoclonal antibody, led to sustained clinical re…

…025 GOLD guidelines, which formally integrate biologics such as dupilumab and mepolizumab for patients with elevations in peripheral eosi…